Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 3, Pages 100118
Publisher
Elsevier BV
Online
2021-05-11
DOI
10.1016/j.esmoop.2021.100118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
- (2021) Antonio Lopez-Beltran et al. Cancers
- Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer
- (2020) Louis Lenfant et al. CURRENT OPINION IN UROLOGY
- IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): Analysis of upper tract (UT) and lower tract (LT) subgroups.
- (2020) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
- (2020) Koichiro Ogihara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes
- (2020) Huili Li et al. Scientific Reports
- Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
- (2020) Julie M. Shabto et al. Cancer Medicine
- Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
- (2020) G. L. Banna et al. Clinical & Translational Oncology
- EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
- (2020) Arsela Prelaj et al. Clinical Lung Cancer
- Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.
- (2020) Sara Elena Rebuzzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Prognostic Role of Serum Lactate Dehydrogenase in Patients With Urothelial Carcinoma: A Systematic Review and Meta-Analysis
- (2020) Minhong Wu et al. Frontiers in Oncology
- Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer
- (2020) Lianghao Zhang et al. MEDICINE
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
- (2020) Giuseppe Luigi Banna et al. Translational Lung Cancer Research
- Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
- (2020) Takashi Kobayashi et al. CANCER SCIENCE
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
- (2019) Cora N. Sternberg et al. EUROPEAN UROLOGY
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- Prognostic Role of Platelet-to-Lymphocyte Ratio in Patients With Bladder Cancer: A Meta-Analysis
- (2019) Xingmu Wang et al. Frontiers in Oncology
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Multi‐omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma
- (2019) Chuanjie Zhang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- PD-L1 assessment in urothelial carcinoma: a practical approach
- (2019) Markus Eckstein et al. Annals of Translational Medicine
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
- (2019) Amin H. Nassar et al. BRITISH JOURNAL OF CANCER
- Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
- (2019) Günter Niegisch BRITISH JOURNAL OF CANCER
- Atézolizumab (Tecentriq ® ) : activité, indication et modalités d’utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques
- (2018) Alice Bernard-Tessier et al. BULLETIN DU CANCER
- Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
- (2018) Carlo Putzu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer
- (2018) Yongyin Gao et al. CLINICA CHIMICA ACTA
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Alona Zer et al. Clinical Lung Cancer
- The Changing Treatment Landscape for Metastatic Urothelial Carcinoma
- (2018) Thomas W. Flaig Journal of the National Comprehensive Cancer Network
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder
- (2018) Yuzhen Luo et al. MEDICINE
- Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients
- (2018) Mihai Dorin Vartolomei et al. WORLD JOURNAL OF UROLOGY
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Combination of the Preoperative Systemic Immune-Inflammation Index and Monocyte-Lymphocyte Ratio as a Novel Prognostic Factor in Patients with Upper-Tract Urothelial Carcinoma
- (2018) Hau-Chern Jan et al. ANNALS OF SURGICAL ONCOLOGY
- The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis
- (2017) Xingxing Tang et al. International Journal of Clinical Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic immune–inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy
- (2017) Li Chen et al. Cancer Management and Research
- Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
- (2015) Sebastiano Buti et al. Future Oncology
- Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer
- (2015) Xuan Hong et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
- (2014) Lorena Rossi et al. ANNALS OF SURGICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started